Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ: PRQR ) with a Outperform and raises the price target from $5 to $6.